Diurnaldiverondormabrol en es it fr

Diurnaldiverondormabrol Brand names, Diurnaldiverondormabrol Analogs

Diurnaldiverondormabrol Brand Names Mixture

  • No information avaliable

Diurnaldiverondormabrol Chemical_Formula


Diurnaldiverondormabrol RX_link

No information avaliable

Diurnaldiverondormabrol fda sheet

Diurnaldiverondormabrol msds (material safety sheet)

Diurnaldiverondormabrol Synthesis Reference

No information avaliable

Diurnaldiverondormabrol Molecular Weight

309.469 g/mol

Diurnaldiverondormabrol Melting Point

< 25 oC

Diurnaldiverondormabrol H2O Solubility

Soluble as HCl salt

Diurnaldiverondormabrol State


Diurnaldiverondormabrol LogP


Diurnaldiverondormabrol Dosage Forms

Tablets (oral, 1 mg)

Diurnaldiverondormabrol Indication

Used for the symptomatic treatment of parkinsonism.

Diurnaldiverondormabrol Pharmacology

Metixene is a tertiary antimuscarinic with actions similar to those of atropine; it also has antihistaminic and direct antispasmodic properties. It is used for the symptomatic treatment of parkinsonism, including the alleviation of the extrapyramidal syndrome induced by other drugs such as phenothiazines, but, like other antimuscarinics, it is of no value against tardive dyskinesias. Metixene has been discontinued.

Diurnaldiverondormabrol Absorption

Absorbed in the gastrointestinal tract following oral administration, however the extent of absorption is not known.

Diurnaldiverondormabrol side effects and Toxicity

Signs of overdose include dilated and sluggish pupils, warm, dry skin, facial flushing, decreased secretions of the mouth, pharynx, nose, and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, and seizures.

Diurnaldiverondormabrol Patient Information

Diurnaldiverondormabrol Organisms Affected

Humans and other mammals